A study to assess and compare safety and tolerability of 3 months treatment with salbutamol administered via MDI containing propellant HFA-152a or HFA-134a in participants ≥ 18 years of age with asthma

1. Participant of ≥18 years of age at the time of signing the informed consent or written informed consent is obtained from each study participant’s legal guardian. 2. Asthma for ≥ 6 months, defined as:

• Documented history of asthma, as defined by Global Initiative for Asthma (GINA) (GINA, 2023]
• Receiving one of the following asthma treatments, at a stable dose (applicable to daily Inhaled corticosteroid (ICS), ICS/Long-acting bronchodilator (LABA), and ICS/LABA/Long-acting muscarinic antagonist [LAMA]), for at least 12 weeks prior to the screening visit, with treatment that is anticipated to remain stable for the duration of the study:

Participants who utilize ICS/SABA combination therapy as reliever therapy, in addition to low to medium dose ICS or ICS/LABA as maintenance, are only eligible if they agree to discontinue their ICS/SABA inhaler for the duration of the study (screening through follow-up). 3. Severity of disease assessed by the investigator by baseline pre-bronchodilator Forced expiratory volume in 1 second (FEV1) 4. Asthma Control Status

• Asthma Control Questionnaire (ACQ) 6 score <1.5 at screening
• Asthma that has remained stable with no severe exacerbations in the last 6 months. Severe exacerbation defined as:

An inpatient hospitalization or Emergency Department (ED) visit because of asthma, requiring systemic corticosteroids. 5. Evidence of reversibility of disease: Airway reversibility is defined as ≥12 percent (%) and ≥200 milliliter (mL) increase in FEV1 within 20 to 60 minutes following up to 4 inhalations of albuterol/salbutamol aerosol. 6. Participants on as-needed SABA only, or daily maintenance ICS (plus as needed SABA):

• With a documented history of reversibility (as defined above) within 2 years will meet this inclusion criterion. Pre- and post-bronchodilator measurements will still be collected at screening to characterize the degree of reversibility.
• Who do not have a documented history of reversibility within the past 2 years will need to demonstrate reversibility during the screening period. ─ SABA should be withheld for ≥6 hours ─ Participants on daily maintenance ICS/LABA or ICS/LABA/LAMA: 7. Participants on daily maintenance ICS/LABA or ICS/LABA/LAMA:
• Do not need to demonstrate reversibility in accordance with the above definition during the screening period. A reversibility maneuver will be performed to characterize the degree of post-bronchodilator change. o SABA should be withheld for ≥6 hours o LABA- and LAMA-containing medications should be withheld for >=24 hours for the characterization of post-bronchodilator change. Participants should be able to withhold SABA for ≥6 hours and LABA-/ LAMA containing medications for ≥24 hours for the purposes of performing screening spirometry.